All In Biotech

Drug Trial Radar · NCT06998524

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Oct 6, 2027

Study completion Sep 6, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).

Conditions

  • Von Willebrand Disease, Type 3

Interventions

  • EmicizumabDrug

    Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W). During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators.

  • von Willebrand Factor (VWF) ConcentratesDrug

    Used according to local labeling or local treatment guidelines.

  • Factor VIII (FVIII) ConcentratesDrug

    Used according to local labeling or local treatment guidelines.

  • von Willebrand Factor (VWF) and Factor VIII (FVIII) ConcentratesDrug

    Used according to local labeling or local treatment guidelines.

  • Bypassing AgentsDrug

    Used according to local labeling or local treatment guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleed Rate (ABR) for Treated Bleeds in the Randomized ArmsTime frame: From Baseline to at least 24 weeks

Locations

30 sites in 14 countries. Site status is shown where the registry gives one.

  • UC Davis

    Sacramento, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • University of Kentucky Children's Hospital

    Lexington, Kentucky · Recruiting

  • University of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • UZ Leuven Gasthuisberg

    Leuven, Belgium · Recruiting

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Center

    Montreal, Quebec, Canada · Recruiting

  • IPS SURA Industriales Medellín

    Medellín, Colombia · Recruiting

  • Hopital Claude Huriez - CHU Lille

    Lille, France · Recruiting

  • Groupe Hospitalier Necker Enfants Malades

    Paris, France · Recruiting

  • Universitätsklinikum Bonn

    Bonn, Germany · Recruiting

  • Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz

    Duisburg, Germany · Recruiting

  • Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin

    Frankfurt/M., Germany · Recruiting

  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia

    Rome, Lazio, Italy · Recruiting

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy · Recruiting

  • AOU Careggi

    Florence, Tuscany, Italy · Recruiting

  • Kurume University Hospital

    Fukuoka, Japan · Recruiting

  • Nagoya University Hospital

    Nagoya, Japan · Recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Recruiting

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland · Recruiting

  • Charlotte Maxeke Johannesburg Academic Hospital

    Johannesburg, South Africa · Recruiting

  • Hospital Universitario la Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

  • Sahlgrenska Universitetssjukhuset

    Gothenburg, Sweden · Recruiting

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom · Recruiting

  • St Thomas' Hospital

    London, United Kingdom · Recruiting

  • Great Ormond Street Hospital

    London, United Kingdom · Recruiting

  • Manchester Royal Infirmary

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.